secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2024-02-09T23:59:59+00:00
Accession:  0001193125-24-030094
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sutro Biopharma adds $100M to at-the-market equity program via new shelf registration
--------------------------------------------------------------------------------

- Filed prospectus supplement to 2023 Form S-3 shelf, increasing shares available under existing Sales Agreement with Jefferies by $100M.
- Total remaining capacity as of Feb 9, 2024: $29.3M from prior shelf plus $100M new supplement = $129.3M.
- Previously sold $70.7M under the 2021 shelf registration since April 2021.
- Shares sold through Jefferies LLC as sales agent at prevailing market prices.
- Legal opinion on share validity filed as Exhibit 5.1 from Fenwick & West.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000119312524030094/0001193125-24-030094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000119312524030094/d737228d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-030094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer